Brief: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
09/03/2026 11:05
March 9 (Reuters) - ARS Pharmaceuticals Inc SPRY.O: ARS PHARMACEUTICALS Q4 EPS USD -0.42 ARS PHARMACEUTICALS Q4 NET INCOME USD -41.3 MILLION ARS PHARMACEUTICALS Q4 REVENUE USD 28.1 MILLION VERSUS. IBES ESTIMATE USD 25.6 MILLION ARS PHARMACEUTICALS INC - ARS PHARMA TO EXPAND SALES FORCE FROM 106 TO 150 BEGINNING Q2 2026 ARS PHARMACEUTICALS INC - REGULATORY APPROVAL FOR NEFFY IN CANADA EXPECTED Q2 2026, LAUNCH EXPECTED LATER IN 2026 Source text: ID:nGNX6dbN79 Further company coverage: SPRY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ARS Pharmaceuticals
See all newsARS Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doubles
U.S. STOCKS ON THE MOVE-Bumble, Tempus AI, TD Synnex
U.S. STOCKS ON THE MOVE-Bio-Techne, IBM, Apple
ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle